Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Pyrotinib in HER2-positive Gastric Cancer
NCT05070598Phase 2Unknown
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Fragment-Derived Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, pyrotinib in gastric cancer (GC), sponsored by Shengjing Hospital of China Medical University. Status: unknown.
02
Drugs
camrelizumabpyrotinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05070598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05070598.